Clinical Trial Update: A Study Of PF-06263507 In Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of PF-06263507 in advanced solid tumors has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Carcinoma Non-small-cell Lung
• Neoplasms
• Ovarian Neoplasms

Drugs mentioned

• PF-06263507

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Carcinoma, Non Small Cell Lung | Phase 1 | Status: TERMINATED | Results posted: 2016-06-24